Antimicrobial dosing strategies in critically ill patients with acute kidney injury and high-dose continuous veno-venous hemofiltration

Current Opinion in Critical Care

Volumn 14, Issue 6, 2008, Pages 654-659

  Bouman, Catherine S C ^a  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

Author keywords

Acute kidney injury; Antibiotic dosing; Continuous veno venous hemofiltration

Indexed keywords

ACICLOVIR; AMIKACIN; AMINOGLYCOSIDE ANTIBIOTIC AGENT; AMOXICILLIN; ANTIINFECTIVE AGENT; BETA LACTAM ANTIBIOTIC; CEFTAZIDIME; CEFTRIAXONE; CEFUROXIME; CIPROFLOXACIN; FLUCONAZOLE; GANCICLOVIR; GENTAMICIN; LEVOFLOXACIN; LINEZOLID; MACROLIDE; MEROPENEM; METRONIDAZOLE; OFLOXACIN; OXACILLIN; PENICILLIN G; PIPERACILLIN; POLYPEPTIDE ANTIBIOTIC AGENT; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFAMPICIN; TEICOPLANIN; TETRACYCLINE; TOBRAMYCIN; UNINDEXED DRUG; VANCOMYCIN;

ANTIMICROBIAL THERAPY; CONTINUOUS HEMOFILTRATION; CREATININE CLEARANCE; CRITICAL ILLNESS; CRITICALLY ILL PATIENT; DISEASE SEVERITY; DRUG ANALYSIS; DRUG CLEARANCE; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG MONITORING; FRACTIONATION; HUMAN; KIDNEY INJURY; LOADING DRUG DOSE; MAINTENANCE DRUG DOSE; PREDICTION; REVIEW; TREATMENT RESPONSE;

ANTI-INFECTIVE AGENTS; CREATINE; CRITICAL ILLNESS; DRUG MONITORING; HEMOFILTRATION; HUMANS; KIDNEY FAILURE, ACUTE;

EID: 57149121692     PISSN: 10705295     EISSN: 15317072     Source Type: Journal    
DOI: 10.1097/MCC.0b013e32830f937c     Document Type: Review

References (36)

1. Paterson DL. Restrictive antibiotic policies are appropriate in intensive care units. Crit Care Med 2003; 31 (1 Suppl):S25-S28.
2. Mehrotra R, De GR, Palazzo M. Antibiotic pharmacokinetic and pharmacodynamic considerations in critical illness. Intensive Care Med 2004; 30:2145-2156.
3. Eggimann P, Pittet D. Infection control in the ICU. Chest 2001; 120:2059-2093.
4. Pea F, Viale P, Furlanut M. Antimicrobial therapy in critically ill patients: a review of pathophysiological conditions responsible for altered disposition and pharmacokinetic variability. Clin Pharmacokinet 2005; 44:1009-1034.
5. Uchino S, Kellum JA, Bellomo R, et al. Acute renal failure in critically ill patients: a multinational, multicenter study. J Am Med Assoc 2005; 294: 813-818.
6. Ricci Z, Ronco C, D'Amico G, et al. Practice patterns in the management of acute renal failure in the critically ill patient: an international survey. Nephrol Dial Transplant 2006; 21:690-696.
7. Uchino S, Bellomo R, Morimatsu H, et al. Continuous renal replacement therapy: a worldwide practice survey. The beginning and ending supportive therapy for the kidney (B. E. S. T. kidney) investigators. Intensive Care Med 2007; 33:1563-1570. The largest prospective multicenter study on CRRT practice patterns in 23 countries.
8. Bouman CS, van Kan HJ, Koopmans RP, et al. Discrepancies between observed and predicted continuous venovenous hemofiltration removal of antimicrobial agents in critically ill patients and the effects on dosing. Intensive Care Med 2006; 32:2013-2019.
9. Pea F, Viale P, Pavan F, Furlanut M. Pharmacokinetic considerations for antimicrobial therapy in patients receiving renal replacement therapy. Clin Pharmacokinet 2007; 46:997-1038. Review of human studies on the pharmacokinetics of antibiotics during CRRT.
10. Davenport A, Bouman C, Kirpalani A, et al. Delivery of renal replacement therapy in acute kidney injury: what are the key issues? Clin J Am Soc Nephrol 2008; 3:869-875. Recommendations for dose and mode of renal replacement therapy in critically ill patients with acute kidney injury on the basis of a careful review of the literature.
11. Ronco C, Bellomo R, Homel P, et al. Effects of different doses in continuous veno-venous haemofiltration on outcomes of acute renal failure: a prospective randomised trial. Lancet 2000; 356:26-30.
12. Mueller BA, Pasko DA, Sowinski KM. Higher renal replacement therapy dose delivery influences on drug therapy. Artif Organs 2003; 27:808-814.
13. Bugge JF. Pharmacokinetics and drug dosing adjustments during continuous venovenous hemofiltration or hemodiafiltration in critically ill patients. Acta Anaesthesiol Scand 2001; 45:929-934.
14. Schetz M. Drug dosing in continuous renal replacement therapy: general rules. Curr Opin Crit Care 2007; 13:645-651. Review of the principles of drug dosing during continuous renal replacement therapy.
15. Bellomo R, Ronco C. Continuous renal replacement therapy in the intensive care unit. Intensive Care Med 1999; 25:781-789.
16. Bouman CS, van Olden RW, Stoutenbeek CP. Cytokine filtration and adsorption during pre and postdilution hemofiltration in four different membranes. Blood Purif 1998; 16:261-268.
17. Marshall MR. Current status of dosing and quantification of acute renal replacement therapy. Part 2: dosing paradigms and clinical implementation. Nephrology (Carlton) 2006; 11:181-191.
18. Tian Q, Gomersall CD, Wong A, et al. Effect of drug concentration on adsorption of levofloxacin by polyacrylonitrile haemofilters. Int J Antimicrob Agents 2006; 28:147-150.
19. Stalker DJ, Jungbluth GL. Clinical pharmacokinetics of linezolid, a novel oxazolidinone antibacterial. Clin Pharmacokinet 2003; 42:1129-1140.
20. Lau AH, Kronfol NO. Determinants of drug removal by continuous hemofiltration. Int J Artif Organs 1994; 17:373-378.
21. Schetz M, Ferdinande P, Van den BG, et al. Pharmacokinetics of continuous renal replacement therapy. Intensive Care Med 1995; 21:612-620.
22. Bouman CS, Oudemans-van Straaten HM, Schultz MJ, Vroom MB. Hemofiltration in sepsis and systemic inflammatory response syndrome: the role of dosing and timing. J Crit Care 2007; 22:1-12.
23. Bouman CS, Oudemans-van Straaten HM. Timing of renal replacement therapy in critically ill patients with acute kidney injury. Curr Opin Crit Care 2007; 13:656-661. This review discusses renal and nonrenal criteria for timing considering the recent literature and the emerging need of a consensus definition for acute kidney injury.
24. Bouman CS. Dosing of antimicrobial agents in critically-ill patients with acute kidney injury and continuous venvenous haemofiltration. Acta Clin Belg Suppl 2007; 365-370. This study retrospectively shows the discrepancies between observed and predicted total body clearance of antibiotics.
25. Golper TA, Wedel SK, Kaplan AA, et al. Drug removal during continuous arteriovenous hemofiltration: theory and clinical observations. Int J Artif Organs 1985; 8:307-312.
26. Joos B, Schmidli M, Keusch G, Pharmacokinetics of antimicrobial agents in anuric patients during continuous venovenous haemofiltration. Nephrol Dial Transplant 1996; 11:1582-1585.
27. Roberts JA, Paratz J, Paratz E, et al. Continuous infusion of beta-lactam antibiotics in severe infections: a review of its role. Int J Antimicrob Agents 2007; 30:11-18. Review discussing the advantages and disadvantages of continuous infusions of beta-lactam antibiotics.
28. Langgartner J, Vasold A, Gluck T, et al. Pharmacokinetics of meropenem during intermittent and continuous intravenous application in patients treated by continuous renal replacement therapy. Intensive Care Med 2008; 34:1091-1096.
29. Kroh UF. Pharmacokinetic studies in patients on continuous renal replacement therapies. Intensive Care Med 2001; 27:629-630.
30. Reetze-Bonorden P, Bohler J, Keller E. Drug dosage in patients during continuous renal replacement therapy. Pharmacokinetic and therapeutic considerations. Clin Pharmacokinet 1993; 24:362-379.
31. Traunmuller F, Schenk P, Mittermeyer C, et al. Clearance of ceftazidime during continuous venovenous haemofiltration in critically ill patients. J Antimicrob Chemother 2002; 49:129-134.
32. Bergner R, Hoffmann M, Riedel KD, et al. Fluconazole dosing in continuous veno-venous haemofiltration (CVVHF): need for a high daily dose of 800mg. Nephrol Dial Transplant 2006; 21:1019-1023.
33. Pea F, Viale P, Lugano M, et al. Linezolid disposition after standard dosages in critically ill patients undergoing continuous venovenous hemofiltration: a report of 2 cases. Am J Kidney Dis 2004; 44:1097-1102.
34. Thalhammer F, Horl WH. Pharmacokinetics of meropenem in patients with renal failure and patients receiving renal replacement therapy. Clin Pharmacokinet 2000; 39:271-279.
35. Fuhrmann V, Schenk P, Mittermayer C, et al. Single-dose pharmacokinetics of ofloxacin during continuous venovenous hemofiltration in critical care patients. Am J Kidney Dis 2003; 42:310-314.
36. Meyer B, Traunmuller F, Hamwi A, et al. Pharmacokinetics of teicoplanin during continuous hemofiltration with a new and a 24-h used highly permeable membrane: rationale for therapeutic drug monitoring-guided dosage. Int J Clin Pharmacol Ther 2004; 42:556-560.